Rising Pharmaceuticals, an affiliate of Rising Pharma Holdings, announced the approval, launch and immediate commercial availability of Edetate calcium disodium injection. This launch will address a critical commercial shortage of this important therapy in the United States.
Rising’s Edetate calcium disodium injection is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.
“The approval and launch of Rising’s Edetate calcium disodium injection opens access to a critical treatment option for patients exposed to lead poisoning, and further demonstrates Rising’s commitment to addressing product supply shortages for the patients who need them,” said Ira Baeringer, Chief Operating Officer, Rising Pharmaceuticals.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!